⚛️ Mango Enters Advanced Nuclear via Nuclea Merger🥭
Mangoceuticals, Inc. (NASDAQ: $MGRX) has signed a definitive business combination agreement with Nuclea Energy Inc., a Mississauga-based advanced nuclear company developing the lead-cooled Morpheus microreactor. The deal gives Mangoceuticals shareholders exposure to advanced nuclear as AI and data-center power demand accelerates. ⚛️ Morpheus is a lead-cooled, graphite-moderated microreactor scalable from ~3.5 MWe to 50 MWe 🔒 Inherent safety design: near-atmospheric pressure, passive natural-convection cooling, no water or steam 🔋 Patent-pending annular fuel targets refueling cycles up to 5 years vs the 1.5-year industry standard 🚛 Factory-built and transportable by standard rail and road (~3m³ core module) 🏭 Target markets: data centers, defense installations, remote mining, and off-grid communities 🔄 Nuclea holders receive Exchangeable Shares convertible one-for-one into MGRX common stock 📋 Approved by both boards, subject to a 19.99% Nasdaq Cap pending stockholder and Nasdaq approval Following the initial closing, Mangoceuticals intends to file a Form S-4 with the SEC to seek stockholder approval. The transaction is designed to give Nuclea a Nasdaq listing to advance Morpheus toward first-of-a-kind delivery and commercialization.
106 views
0 Comments
Join the conversation with 500,000+ other investors 💸
Create an account to get access to everything Blossom has to offer!
📊 Personalized algorithm based on your investing style, experience level and interests
📈 Powerful portfolio and dividend tracking tools
👀 See what top creators and others in the community are investing in
